Current status and future perspectives for the treatment of resectable locally advanced esophagogastric junction cancer: A narrative review

Table 4 Clinical trials comparing neoadjuvant chemotherapy versus chemoradiotherapy for esophagogastric junction cancer included in this review

Study name	NeoRes[35,36]	POET[37]	Neo-AEGIS[38]
Ref.	Klevebro et al[35,36]	Stahl et al[37]	John et al[38]
Year	2015/2016	2009	2021
Study design	Randomized phase II	Phase III	Phase III
Eligible patients	cT1N+ or cT2-3, M0	cT3-4, M0	cT2-3N0-3M0
	Esophageal or EGJ cancer	EGJ cancer	Esophageal or EGJ cancer
Experimental arm	CF + RT	PLF + RT	CROSS
Control arm	CF	PLF	MAGIC/FLOT
Total number of patients	181	119	377
EGJ cancer patients	17%	100%	NA
Primary outcome	pCR	OS	OS
OS	NA	33 vs 21 mo	NA
pCR rate	24% vs 8%	15.6% vs 2.0%	NA
R0 resection rate	76% vs 64%	69.5% vs 71.5%	NA
Special notes	Equivalent 3-year OS	Study closed early due to low accrual, high in-hospital mortality after chemoradiotherapy	Equivalent 3-year estimated survival probability

EGJ: Esophagogastric junction; pCR: Pathological complete response; CF: Cisplatin + 5-fluorouracil; RT: Radiation therapy; PLF: Paclitaxel + leucovorin + 5-fluorouracil; CROSS: Carboplatin + paclitaxel + radiation therapy; MAGIC: Epirubicin + cisplatin (oxaliplatin) + 5-fluorouracil; FLOT: 5-fluorouracil + leucovorin + oxaliplatin + docetaxel; NA: Not available; OS: Overall survival.